Skip to content

A clinical trial to find out if the STASI™ sponge can better stop bleeding after cleaning diabetic foot wounds compared to regular gauze in people taking blood-thinning medicines

Prospective, Randomized, Investigator Initiated, Controlled Study to determine Haemostatic Efficacy of STASITM Non-Absorbable Sponge to control bleeding after debridement of Diabetic Foot Ulcers as compared to sterile gauze in patients taking Anticoagulants - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/11/096985
Enrollment
20
Registered
2025-11-06
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L974- Non-pressure chronic ulcer of heeland midfoot Health Condition 2: E116- Type 2 diabetes mellitus with other specified complications

Interventions

Intervention1: STASITM Non-Absorbable Sponge: Haemostasis will be assessed at 5 and 10 minutes post-dressing, with treatment deemed successful if bleeding stops without additional measures within 10 m

Sponsors

Dr Rajat Engineer
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Adults male or female subjects aged 18 years and above with type I or II diabetes mellitus. - Ulcer classified as Wagner grade I or II ulcers (more than 2 cm in diameter size and less than 10cm, and a duration of more than 6 weeks). - Patients with good extremity circulation status, palpable pulse or confirmation with doppler sonography at the ankle (dorsalis pedis artery or posterior tibial artery). - Received anticoagulation therapy due to diabetic vasculopathy or systemic disease. - Patients with ability to understand and provide written, signed and dated informed consent form, which must have been obtained prior to screening. - Patients willing to comply with the protocol requirements.

Exclusion criteria

Exclusion criteria: - Hypersensitivity to STASITM Non-Absorbable Sponge or other components. - Pregnant or lactating women. - Patients undergoing Immunosuppressant therapy or systemic cardiopulmonary disease. - Refusal or inability to provide consent.

Design outcomes

Primary

MeasureTime frame
Proportion of patients in each group achieving complete haemostasis at 10 minutes after dressing application, without the need for additional interventionsTimepoint: 10 mins after application

Secondary

MeasureTime frame
- Proportion of patients achieving complete haemostasis at 5 minutes - Percentage of patients experiencing complications defined as rebleeding of hematoma Timepoint: 5 min and 10 mins after application

Countries

India

Contacts

Public ContactDr Rajat K Engineer

Shraddha Multispeciality Hopsital

drrajatengineer8@gmail.com02764221222

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026